During the past decade, Hangzhou first people's Hospital conducted 68 clinical trials. In the 10-year time frame, 68 clinical trials started and 4 clinical trials were completed, i.e. on average, 5.9% percent of trials that started reached the finish line to date. In the past 5 years, 42 clinical trials started and 3 clinical trials were completed. i.e. 7.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hangzhou first people's Hospital" #1 sponsor was "First People's Hospital of Hangzhou" with 24 trials, followed by "BeiGene" with 3 trials sponsored, "Reistone Biopharma Company Limited" with 3 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored and "Jiangsu HengRui Medicine Co., Ltd." with 2 trials sponsored. Other sponsors include 38 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hangzhou first people's Hospital" #1 collaborator was "First People's Hospital of Hangzhou" with 4 trials as a collaborator, "Second Affiliated Hospital of Wenzhou Medical University" with 3 trials as a collaborator, "First Affiliated Hospital of Zhejiang University" with 2 trials as a collaborator, "Guangdong Provincial People's Hospital" with 2 trials as a collaborator and "Qilu Hospital of Shandong University" with 2 trials as a collaborator. Other collaborators include 75 different institutions and companies that were collaborators in the rest 84 trials.

According to Clinical.Site data, the most researched conditions in "Hangzhou first people's Hospital" are "Cholangiocarcinoma" (4 trials), "Choledocholithiasis" (3 trials), "Complication" (3 trials), "Healthy" (3 trials) and "Non-small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "Hangzhou first people's Hospital" in a lesser frequency.

Most popular intervention types in "Hangzhou first people's Hospital" are "Drug" (43 trials), "Device" (13 trials), "Procedure" (12 trials), "Other" (8 trials) and "Radiation" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "radiofrequency ablation" (3 trials), "CM310" (2 trials), "Cisplatin" (2 trials) and "Docetaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hangzhou first people's Hospital" are 75 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are 29 active trials in "Hangzhou first people's Hospital". 3 are not yet recruiting, 18 are recruiting, 6 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 32 completed trials in Hangzhou first people's Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hangzhou first people's Hospital, 4 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 27 trials that are defined as “Not Applicable".